SCHEMBL15765229

SCHEMBL15765229

O=C(c1ncc(Br)cc1Cl)N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.51
TSHR P16473 2/20 0.51
ESR2 Q92731 1/20 0.51
MAPT P10636 2/20 0.48
PKM P14618 1/20 0.48
HTT P42858 1/20 0.48
KDM4E B2RXH2 2/20 0.47
HSP90AA1 P07900 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
AKR1C3 P42330 1/20 0.45
NSD2 O96028 1/20 0.45
POLB P06746 1/20 0.45
NR4A1 P22736 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LRRK2 Q5S007 1/20 0.44
PHGDH O43175 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19657270 0.86 HPGD (0.52) HPGDTSHRMAPTPKMHTT
SCHEMBL30542228 0.83 TSHR (0.51) HPGDTSHRESR2MAPTHTT
SCHEMBL15765190 0.83 TSHR (0.51) HPGDTSHRESR2MAPTHTT
SCHEMBL19657271 0.80 HPGD (0.46) HPGDTSHRMAPTPKMHTT
SCHEMBL23580964 0.78 RORC (0.39) HPGDHTTLRRK2
SCHEMBL15228320 0.75 HPGD (0.55) HPGDTSHRESR2MAPTKDM4E
SCHEMBL2379474 0.75 SMN1; SMN2 (0.70) HPGDTSHRESR2MAPTKDM4E
SCHEMBL15227469 0.74 PHGDH (0.48) HPGDTSHRMAPTPKMHTT
SCHEMBL23912759 0.74 HTT (0.51) HPGDTSHRESR2MAPTPKM
SCHEMBL3376149 0.74 TSHR (0.51) HPGDTSHRESR2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 US disclosed
WO-2014085607-A1 SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2014-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof BCL6, MALT1, BCL3 HPGD 1345/4885TSHR 4801/4885ESR2 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.